Skip to content
Tuesday, November 17, 2026 · Today’s edition, 6:30 a.m. ETTue, Nov 17 · 6:30 a.m. editionSign inMy Desk 0EditionsSign in
IBBISharesINDEX

iShares Biotechnology ETF

$207.98-2.13% vs prior close
16022152-WK

Price through Nov 16, 2026 · Flows through Nov 13, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Nov 16, 2026. Holdings snapshot retrieved Nov 16, 2026.

The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

IBB price

Source: Market tape, daily closes; price return, distributions not reinvested
Table
DateIBB close
Aug 17, 2026$201.93
Aug 18, 2026$203.56
Aug 19, 2026$216.96
Aug 20, 2026$210.83
Aug 21, 2026$213.56
Aug 24, 2026$212.53
Aug 25, 2026$216.40
Aug 26, 2026$215.23
Aug 27, 2026$214.80
Aug 28, 2026$208.95
Aug 31, 2026$209.05
Sep 1, 2026$210.82
Sep 2, 2026$213.80
Sep 3, 2026$213.81
Sep 4, 2026$211.92
Sep 8, 2026$207.33
Sep 9, 2026$205.49
Sep 10, 2026$202.64
Sep 11, 2026$202.93
Sep 14, 2026$204.60
Sep 15, 2026$202.00
Sep 16, 2026$202.40
Sep 17, 2026$207.07
Sep 18, 2026$204.56
Sep 21, 2026$207.16
Sep 22, 2026$210.81
Sep 23, 2026$206.60
Sep 24, 2026$209.25
Sep 25, 2026$209.77
Sep 28, 2026$210.71
Sep 29, 2026$211.04
Sep 30, 2026$210.53
Oct 1, 2026$205.96
Oct 2, 2026$205.29
Oct 5, 2026$207.96
Oct 6, 2026$203.10
Oct 7, 2026$203.34
Oct 8, 2026$200.48
Oct 9, 2026$206.49
Oct 12, 2026$204.26
Oct 13, 2026$200.02
Oct 14, 2026$203.25
Oct 15, 2026$207.41
Oct 16, 2026$201.99
Oct 19, 2026$204.06
Oct 20, 2026$210.50
Oct 21, 2026$211.55
Oct 22, 2026$209.54
Oct 23, 2026$207.74
Oct 26, 2026$208.69
Oct 27, 2026$212.20
Oct 28, 2026$216.35
Oct 29, 2026$217.86
Oct 30, 2026$217.61
Nov 2, 2026$213.79
Nov 3, 2026$215.47
Nov 4, 2026$221.13
Nov 5, 2026$209.99
Nov 6, 2026$213.63
Nov 9, 2026$219.57
Nov 10, 2026$217.18
Nov 11, 2026$218.14
Nov 12, 2026$213.43
Nov 13, 2026$212.50
Nov 16, 2026$207.98

Weekly net flows, 3M

Net inflow over the range: +$449M

  • Inflow / above zero
  • Outflow / below zero
Aug 10Aug 17Aug 24Aug 31Sep 7Sep 14Sep 21Sep 28Oct 5+$468.1MOct 12Oct 19Oct 26Nov 2−$29.8MNov 9Aug 10Aug 24Sep 7Sep 21Oct 5+$468.1MOct 19−$29.8MNov 9Aug 10Sep 7Oct 5+$468.1M−$29.8MNov 9
Source: Daily creation and redemption records
Show as table
LabelValue ($)
Aug 10$88.9M
Aug 17$54.9M
Aug 24$11.2M
Aug 31$66.4M
Sep 7$61.8M
Sep 14$19.4M
Sep 21−$61.7M
Sep 28$145.5M
Oct 5−$332.5M
Oct 12$468.1M
Oct 19−$79.5M
Oct 26$263.2M
Nov 2−$227M
Nov 9−$29.8M
The desk’s read

Money is leaving — −$73M in net outflows over the past month, about 0.7% of the fund's asset base, while the price has returned +23.2% so far this year. At 0.44% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.

COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH

$11.1Bassets under management
0.44%expense ratio · $44 per $10,000 a year
−$73Mnet flow, trailing month
2Mavg daily volume, 30 days
243holdings · US-domiciled
2001listed February 5, 2001 · beta 0.87
The book at a glance
GILD-0.3%AMGN-0.7%VRTX-0.2%REGN-0.3%MRNA-3.6%ARGX-0.9%NTRA-9.6%BIIB-0.7%ONC-1.3%RVMD-3.1%ILMN-4.4%GMAB+0.4%INSM+1.4%UTHR-0.6%INCY-0.6%ALNY-3.2%ROIV-2.3%ASND-1.3%NBIX-1.2%EXEL-2.8%CRL-0.7%MEDP-0.9%BBIO-1.2%HALO-3.8%RGEN-3.0%KYMR

CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS

Holdings
#HoldingWeightPriceDay52-wk
1GILDGILEAD SCIENCES8.96%$167.58-0.3%
2AMGNAMGEN8.48%$462.32-0.7%
3VRTXVERTEX PHARMACEUTICALS7.78%$537.79-0.2%
4REGNREGENERON PHARMACEUTICALS6.51%$952.40-0.3%
5MRNAMODERNA5.84%$215.27-3.6%
6ARGXARGENX SE3.77%$950.95-0.9%
7NTRANATERA3.00%$288.48-9.6%
8BIIBBIOGEN2.54%$251.65-0.7%
9ONCBeiGene2.42%$411.29-1.3%
10RVMDREVOLUTION MEDICINES2.35%$166.87-3.1%
11ILMNILLUMINA2.18%$198.00-4.4%
12GMABGENMAB A1.98%$51.57+0.4%
13INSMINSMED1.75%$122.88+1.4%
14UTHRUNITED THERAPEUTICS1.70%$587.88-0.6%
15INCYINCYTE1.69%$120.27-0.6%

The full book, free with one sign-in.

Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.

Sign in to see all 243

Sector weights

  • Health Care99.9%
  • Cash and/or Derivatives0.11%
Source: Portfolio composition, latest disclosure
Show as table
ItemValue (%)
Health Care99.9%
Cash and/or Derivatives0.11%

Country weights

  • United States89.53%
  • Belgium3.8%
  • China2.79%
  • Denmark1.98%
  • Germany0.57%
  • France0.44%
  • United Kingdom0.23%
  • Canada0.2%
Source: Portfolio composition, latest disclosure
Show as table
ItemValue (%)
United States89.53%
Belgium3.8%
China2.79%
Denmark1.98%
Germany0.57%
France0.44%
United Kingdom0.23%
Canada0.2%
Performance
1 week-4.2%
1 month+3.0%
3 months+4.9%
6 months+24.7%
YTD+23.2%
1 year—
3 years—

PRICE RETURN, DISTRIBUTIONS NOT REINVESTED

Net flows
1 week+$101M
1 month−$73M
3 months+$360M
YTD+$554M
1 year+$1.2B

CREATION/REDEMPTION DOLLARS, DAILY RECORDS

Monthly net flows

  • Inflow / above zero
  • Outflow / below zero
+$1.6BNov−$209.7MDec+$16.5MJan+$101.3MFeb−$338.1MMar−$171.2MApr−$112MMay+$560MJul+$151.3MAug+$654.9MSep−$52.2MOct−$256.8MNov+$1.6BNovDecJanFebMarAprMayJulAugSepOct−$256.8MNov+$1.6BNovJanMarMayAug−$256.8MNov
Source: Daily creation/redemption records, trailing twelve months
Show as table
LabelValue ($)
Nov$1.6B
Dec−$209.7M
Jan$16.5M
Feb$101.3M
Mar−$338.1M
Apr−$171.2M
May−$112M
Jul$560M
Aug$151.3M
Sep$654.9M
Oct−$52.2M
Nov−$256.8M
The risk read
32%realized volatility, 30 days (annualized)
24%realized volatility, 1 year
-9.7%deepest fall from a peak, 1 year
-5.9%latest close versus that peak

The top holding is 9.0% of the book; the top ten carry 52%. Spread across 239+ names, it behaves like roughly 27 equally-weighted positions.

VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK

Options tape
2Kcalls · latest snapshot
358puts · latest snapshot
0.22put/call ratio
1.6Mshares traded
Most-traded holdings, options premiumBullishBearish
MRNA MODERNA$30M$26M
NTRA NATERA$20M$1M
SMMT SUMMIT THERAPEUTICS$5M$5M
CGON CG ONCOLOGY INC$3M$6M
TEM TEMPUS AI INC$3M$5M

TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES

The case against IBB

Due diligence cuts both ways. These funds sit on the same shelf and beat IBB on at least one dimension that matters — the fee, the asset base, or where the money is going.

FundFeeAssetsFlow, 1MThe case
IVV iShares Core S&P 500 ETF0.03%$879.1B+$10.1B-41bp on fee · 79× the assets · +$10.1B in over the monthHead-to-head
SPDW SPDR Portfolio Developed World ex-US ETF0.03%$41.6B+$917M-41bp on fee · 4× the assets · +$917M in over the monthHead-to-head
BBUS JPMorgan BetaBuilders U.S. Equity ETF0.02%$9.7B+$356M-42bp on fee · +$356M in over the monthHead-to-head
SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF0.03%$18.4B+$199M-41bp on fee · 2× the assets · +$199M in over the monthHead-to-head
SPTM State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF0.03%$14.2B+$235M-41bp on fee · +$235M in over the monthHead-to-head
Sign in to save this to The RecordA timestamped copy for the file — documentation, not advice.

Watch & listen: IShares

From the manager behind IBBAll of Watch & Listen
ETF Dailyfrom Private Wealth Daily

ETF launches, fund research, and market coverage in your inbox every morning. Free.

Free. Every morning. Unsubscribe from any edition in one click.